Drug Trial Radar · NCT06839339
Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD
Last checked: Nov 19, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Feb 18, 2025
Primary completion
Sep 30, 2026
Study completion Jan 30, 2027
Sponsor
- Lead sponsor
- Beijing Anlong Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II study is designed to evaluate the efficacy and safety of AL-001 ophthalmic injection in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will be randomized in Cohorts 1 and 2 to receive AL-001 administered via suprachoroidal space injection, Cohort 3 to receive Aflibercept.
Conditions
- Wet Age-related Macular Degeneration (wAMD)
Interventions
AL-001Drug
Administered via suprachoroidal space injection.
AfliberceptDrug
Intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the effect of AL-001 on BCVATime frame: Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences & Peking Union Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.